tirzepatide fda compounding pharmacy Oral | Starts at $279/mo FDA Allows Compounded Tirzepatide During

Korsten M, Matsuzaki S, Feinman L, Lieber C

The strategic differentiation thesis that emerged from the analysis: CT-388 is best positioned as the "Balanced Precision Dual Agonist," differentiated from tirzepatide by equimolar GIP:GLP-1 engagement (1:1 vs 9:1), a distinct peptide scaffold with independent IP, and a five-year extended exclusivity window

It works by mimicking the actions of GLP-1, a hormone that helps regulate blood sugar and appetite, and GIP, which also assists in glucose and lipid metabolism

Remember, investing in your health can save you money in the future by helping prevent problems caused by being overweight